Skip to main content

Advertisement

SpringerLink
Log in

The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study

  • Original article
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

Abstract

Migraine is a disabling disorder that affects the quality of life of patients. Different medications have been used in prevention of migraine headache. In this study, we evaluated the effectiveness of magnesium oxide in comparison with valproate sodium in preventing migraine headache attacks. This is a single-center, randomized, controlled, crossover trial which is double-blind, 24-week, 2-sequence, 2-period, 2-treatment. After patient randomization into two sequences, the intervention group received magnesium oxide 500 mg and the control group received valproate sodium 400 mg two tablets each day (every 12 h) for 8 weeks. The primary efficacy variable was reduction in the number of migraine attacks and number of days with moderate or severe headache and hours with headache (duration) per month in the final of 8 weeks in comparison with baseline. Seventy patients were randomized and seven dropped out, leaving 63 for analysis. In an intention-to-treat analysis, 31 patients were in group 1 (magnesium oxide–valproate) and 32 patients were in group 2 (valproate–magnesium oxide). The mean number of migraine attacks and days per month was 1.72 ± 1.18 and 2.09 ± 1.70, with a mean duration of 15.50 ± 21.80 h in magnesium group and 1.27 ± 1.27 and 2.22 ± 1.96, with a mean duration 13.38 ± 14.10 in valproate group. This study has shown that 500 mg magnesium oxide appears to be effective in migraine prophylaxis similar to valproate sodium without significant adverse effect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Martin VT, Behbehani MM (2001) Towards a rational understanding of migraine trigger factors. Med Clin N Am 85:911–941

    Article  CAS  Google Scholar 

  2. Lipton RB, Liberman JN, Kolodner KB, igal ME, Dowson A, Stewart WF (2003) Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia 23:441–450

    Article  CAS  Google Scholar 

  3. Stewart WF, Shechter A, Rasmussen BK (1994) Migraine prevalence. A review of population-based studies. Neurology 44 (6 Suppl 4):S17–S23

    CAS  PubMed  Google Scholar 

  4. Shahbeigi S, Fereshtehnejad SM, Mohammadi N et al (2013) Epidemiology of headaches in Tehran urban area: a population based cross-sectional study in district 8, year 2010. Neurol Sci 34:1157–1166

    Article  Google Scholar 

  5. Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache 2006;46:642–648

    Article  Google Scholar 

  6. Karimi N, Tavakoli M, Yazdani Charati J, Shamsizade M (2017) Single-dose intravenous sodium valproate (Depakine) versus dexamethasone for the treatment of acute migraine headache: a doubleblind randomized clinical trial. Clin Exp Emerg Med 4 (2):1–8

    Google Scholar 

  7. Rybicka M, Baranowska-Bosiacka I, Żyluk B, Nowacki P, Chlubek D (2012) The role of magnesium in migraine pathogenesis. Potential use of magnesium compounds in prevention and treatment of migraine headaches. J Elementol 17:345–356

    Google Scholar 

  8. Welch KM, Ramadan NM (1995) Mitochondria, magnesium and migraine. J Nneurol Sci 134:9–14

    Article  CAS  Google Scholar 

  9. Schoenen J, Sianard -Gainko J, Lenaerts M (1991) Blood magnesium levels in migraine. Cephalalgia 11:97–99

    Article  CAS  Google Scholar 

  10. Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G (1991) Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 31:298–301 24

    Article  CAS  Google Scholar 

  11. Baudouin-Legros M, Dard B, Guichency P (1986) Hyperreactivity of platelets from spontaneously hypertensive rats. Role of external magnesium. Hypertension 8:694–699

    Article  CAS  Google Scholar 

  12. Altura BT, Altura BM (1989) Withdrawal of magnesium causes vasospasm while elevated magnesium produced relaxation of tone in cerebral arteries. Neurosci Lett 20:323–327

    Article  Google Scholar 

  13. Weglicki WB, Phillips TM (1992) Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis. Am J Physiol 263:R734–R737

    CAS  PubMed  Google Scholar 

  14. Choi H, Parmar N (2014) The use of intravenous magnesium sulphate for acute migraine: meta-analysis of randomized controlled trials. Eur J Emerg Med 21:2–9

    PubMed  Google Scholar 

  15. Peikert A, Wilimzig C, Köhne-Volland F (1996) Prophylaxis of migraine with oral magnesium: results from a prospective, multicenter, placebo-controlled and double-blind randomized study. Cephalalgia 16:257–263

    Article  CAS  Google Scholar 

  16. Pfaffenrath V, Wessely P, Meyer C, Isler HR, Evers S, Grotemeyer KH, Taner Z, Soycal D, G’bell H, Fischer M (1996) Magnesium in the prophylaxis of migraine—a double-blind, placebo-controlled study. Cephalalgia 16:436–440

    Article  CAS  Google Scholar 

  17. Koseoglu E, Talashoglu A, Gonul AS, Kula M (2008) The effects of magnesium prophylaxis in migraine without aura. Magnes Res 21:101–108

    CAS  PubMed  Google Scholar 

  18. Maizels M, Blumenfeld A, Burchette R (2004) A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 44:885–890

    Article  Google Scholar 

  19. Zhou Y, Gao L (1998) Flunarizine combined with magnesium polarization liquid on treating refractory migraine. Clin Focus 13:664

    Google Scholar 

  20. Hu CS, Zhou LB (2011) Observation of clinical effects of magnesium valproate combined with venlafaxine HCl in 54 individuals with migraine. China Mod Med 18:62

    Google Scholar 

  21. Bian X, Zhu Y, Xia J, Ai HJ, Guo QY, Lu LB, Zhang QW (2013) Clinical observation om potassium magnesium asparate oral soluation combined with flinarizine capsule for migraine prophylaxis. J Comm Med 11:6–7

    CAS  Google Scholar 

  22. Tang XY, Lin WZ, Zheng XM, Liu CS (1998) Observation of effects of nimodipine and magnesium sulfate combination for treating migraine. J Qiqihar Med Coll 19:5–6

    Google Scholar 

  23. Alghadeer SM (2016) The efficacy of different oral magnesium supplements for migraine prevention: a literature review. Indones J Pharm 27 (3):174–182

    Article  CAS  Google Scholar 

  24. Chiu HY, Yeh TH, Huang YC, Chen PY (2016) Effects of intravenous and oral magnesium on reducing migraine: a meta-analysis of randomized controlled trials. Pain Physician 19:E97–E112

    PubMed  Google Scholar 

  25. Pringsheim T, Davenport W, Mackie G et al (2012) Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci 39:S1–S59

    Article  Google Scholar 

  26. Teigen L, Boes ChJ (2015) An evidence-based review of oral magnesium supplementation in the preventive treatment of migraine. Cephalalgia 35 (10):912–922

    Article  Google Scholar 

  27. Hering R, Kuritzky A (1992) Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 12:81–84

    Article  CAS  Google Scholar 

  28. International Headache Society Committee on Clinical Trials in Migraine (2012) Guidelines for controlled trials of drugs in migraine. Third edition. A guide for investigators. Cephalalgia 32 (1):6–38

    Article  Google Scholar 

  29. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edn (beta version). Cephalalgia 2013; 33:629–808

    Article  Google Scholar 

  30. Bayliss MS, Dewey JE, Dunlap I, Batenhorst AS, Cady R, Diamond ML, Sheftell F (2003 Dec) A study of the feasibility of Internet administration of a computerized health survey: the headache impact test (HIT). Qual Life Res 12 (8):953–961

    Article  CAS  Google Scholar 

  31. Stewart WF, Lipton RB, Kolodner K (2003) Migraine disability assessment (MIDAS) score: relation to headache frequency, pain intensity, and headache symptoms. Headache 43 (3):258–265

    Article  Google Scholar 

  32. Ghorbani A, Chitsaz A (2011) Comparison of validity and reliability of the migraine disability assessment (MIDAS) versus headache impact test (HIT) in an Iranian population. Iran J Neurol 10:39–42

    PubMed  PubMed Central  Google Scholar 

  33. Wang F, Van Den Eeden SK, Ackerson LM, Salk SE, Reince RH, Elin RJ (2003) Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache 43 (6):601–610

    Article  Google Scholar 

  34. Tarighat Esfanjani A, Mahdavi R, Ebrahimi Mameghani M, Talebi M, Nikniaz Z, Safaiyan A (2012) The effects of magnesium, l-carnitine, and concurrent magnesium-l-carnitine supplementation in migraine prophylaxis. Biol Trace Elem Res 150 (1–3):42–48

    Article  Google Scholar 

  35. Gaul C, Diener H-C, Danesch U (2015) Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain 16 (1):32

    Article  Google Scholar 

  36. Demirkaya S, Dora B, Topcuoglu MA, Vural O, U HU (2001) A comparative study of magnesium, flunarizine and amitriptyline in the prophylaxis of migraine. J Headache Pain 1 (2000):179–186

    Google Scholar 

  37. Mauskop A, Altura BT, Altura BM (2002) Serum ionized magnesium levels and serum ionized calcium/ionized magnesium ratios in women with menstrual migraine. Headache 42:242–248

    Article  Google Scholar 

  38. Abraham GE, Lubran MM (1981) Serum and red cell magnesium levels in patients with premenstrual tension. Am J Clin Nutr 34 (11):2364–2366

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to thank all the patients who participated in this study and Alimohammady pharmacy due to providing drugs and the Research Vice-Chancellor of Maznadaran University of Medical Sciences for their financial supports and also Clinical Research Development Unit of Bou Ali Sina Hospital to approve this proposal.

Author information

Authors and Affiliations

  1. School of Medicine, Immunogenetics Research Center, Clinical Research Development Unit of Bou Ali Sina Hospital, Mazandaran University of Medical Sciences, Pasdaran boulevard, Sari, Mazandaran Province, Iran

    Narges Karimi

  2. Mazandarn University of Medical Sciences, Sari, Iran

    Azadeh Razian

  3. Department of Epidemiology and Biostatistics, School Of Medicine, Urmia University of Medical Sciences, Urmia, Iran

    Mohammad Heidari

Authors
  1. Narges Karimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Azadeh Razian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohammad Heidari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Narges Karimi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karimi, N., Razian, A. & Heidari, M. The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study. Acta Neurol Belg 121, 167–173 (2021). https://doi.org/10.1007/s13760-019-01101-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13760-019-01101-x

Keywords

Search

Navigation